| Characteristic . | Poor Outcome, % (Proportion) . | Risk Ratio (95% CI) . |
|---|---|---|
| Sex | ||
| Male | 9.7 (15/155) | 1.00 |
| Female | 14.3 (15/105) | 1.48 (.75–2.89) |
| Age, y | ||
| <21 | 3.8 (1/26) | 1.00 |
| 21–30 | 5.5 (4/73) | 1.42 (.17–12.17) |
| 31–40 | 15.5 (13/84) | 4.02 (.55–29.31) |
| 41–50 | 17.1 (7/41) | 4.44 (.58–34.03) |
| ≥51 | 14.7 (5/34) | 3.82 (.48–30.77) |
| Prior history of tuberculosis | ||
| No | 10.9 (24/220) | 1.00 |
| Yes | 15.0 (6/40) | 1.38 (.60–3.15) |
| Treatment category | ||
| New | 11.7 (26/223) | 1.00 |
| Retreatment | 10.8 (4/37) | 0.93 (.34–2.50) |
| HIV status | ||
| Negative | 4.3 (5/116) | 1.00 |
| Positive | 17.1 (24/140) | 3.98 (1.57–10.10) |
| Phenotypic DST result | ||
| INH and RIF susceptible | 9.5 (21/221) | 1.00 |
| INH monoresistance | 27.3 (3/11) | 2.87 (1.01–8.18) |
| RIF monoresistance | 25.0 (1/4) | 2.63 (.46–15.07) |
| Multidrug resistance | 80.0 (4/5) | 8.42 (4.63–15.31) |
| Resistance mutation frequency, % | ||
| <0.1 | 9.8 (19/193) | 1.00 |
| 0.1–4.9 (micro-heteroresistance) | 3.2 (1/31) | 0.33 (.05–2.36) |
| 5.0–94.9 (macro-heteroresistance) | 0.0 (0/2) | 0.00 (Undefined) |
| ≥95 (fixed resistance) | 46.7 (7/15) | 4.74 (2.38–9.44) |
| Strain heterogeneity | ||
| Single strain | 11.0 (19/173) | 1.00 |
| Possible mixed strains | 9.1 (6/66) | 0.83 (.35–1.98) |
| Mixed strains | 23.8 (5/21) | 2.17 (.90–5.20) |
| Characteristic . | Poor Outcome, % (Proportion) . | Risk Ratio (95% CI) . |
|---|---|---|
| Sex | ||
| Male | 9.7 (15/155) | 1.00 |
| Female | 14.3 (15/105) | 1.48 (.75–2.89) |
| Age, y | ||
| <21 | 3.8 (1/26) | 1.00 |
| 21–30 | 5.5 (4/73) | 1.42 (.17–12.17) |
| 31–40 | 15.5 (13/84) | 4.02 (.55–29.31) |
| 41–50 | 17.1 (7/41) | 4.44 (.58–34.03) |
| ≥51 | 14.7 (5/34) | 3.82 (.48–30.77) |
| Prior history of tuberculosis | ||
| No | 10.9 (24/220) | 1.00 |
| Yes | 15.0 (6/40) | 1.38 (.60–3.15) |
| Treatment category | ||
| New | 11.7 (26/223) | 1.00 |
| Retreatment | 10.8 (4/37) | 0.93 (.34–2.50) |
| HIV status | ||
| Negative | 4.3 (5/116) | 1.00 |
| Positive | 17.1 (24/140) | 3.98 (1.57–10.10) |
| Phenotypic DST result | ||
| INH and RIF susceptible | 9.5 (21/221) | 1.00 |
| INH monoresistance | 27.3 (3/11) | 2.87 (1.01–8.18) |
| RIF monoresistance | 25.0 (1/4) | 2.63 (.46–15.07) |
| Multidrug resistance | 80.0 (4/5) | 8.42 (4.63–15.31) |
| Resistance mutation frequency, % | ||
| <0.1 | 9.8 (19/193) | 1.00 |
| 0.1–4.9 (micro-heteroresistance) | 3.2 (1/31) | 0.33 (.05–2.36) |
| 5.0–94.9 (macro-heteroresistance) | 0.0 (0/2) | 0.00 (Undefined) |
| ≥95 (fixed resistance) | 46.7 (7/15) | 4.74 (2.38–9.44) |
| Strain heterogeneity | ||
| Single strain | 11.0 (19/173) | 1.00 |
| Possible mixed strains | 9.1 (6/66) | 0.83 (.35–1.98) |
| Mixed strains | 23.8 (5/21) | 2.17 (.90–5.20) |
Abbreviations: CI, confidence interval; DST, drug susceptibility test; HIV, human immunodeficiency virus; INH, isoniazid; RIF, rifampicin.
| Characteristic . | Poor Outcome, % (Proportion) . | Risk Ratio (95% CI) . |
|---|---|---|
| Sex | ||
| Male | 9.7 (15/155) | 1.00 |
| Female | 14.3 (15/105) | 1.48 (.75–2.89) |
| Age, y | ||
| <21 | 3.8 (1/26) | 1.00 |
| 21–30 | 5.5 (4/73) | 1.42 (.17–12.17) |
| 31–40 | 15.5 (13/84) | 4.02 (.55–29.31) |
| 41–50 | 17.1 (7/41) | 4.44 (.58–34.03) |
| ≥51 | 14.7 (5/34) | 3.82 (.48–30.77) |
| Prior history of tuberculosis | ||
| No | 10.9 (24/220) | 1.00 |
| Yes | 15.0 (6/40) | 1.38 (.60–3.15) |
| Treatment category | ||
| New | 11.7 (26/223) | 1.00 |
| Retreatment | 10.8 (4/37) | 0.93 (.34–2.50) |
| HIV status | ||
| Negative | 4.3 (5/116) | 1.00 |
| Positive | 17.1 (24/140) | 3.98 (1.57–10.10) |
| Phenotypic DST result | ||
| INH and RIF susceptible | 9.5 (21/221) | 1.00 |
| INH monoresistance | 27.3 (3/11) | 2.87 (1.01–8.18) |
| RIF monoresistance | 25.0 (1/4) | 2.63 (.46–15.07) |
| Multidrug resistance | 80.0 (4/5) | 8.42 (4.63–15.31) |
| Resistance mutation frequency, % | ||
| <0.1 | 9.8 (19/193) | 1.00 |
| 0.1–4.9 (micro-heteroresistance) | 3.2 (1/31) | 0.33 (.05–2.36) |
| 5.0–94.9 (macro-heteroresistance) | 0.0 (0/2) | 0.00 (Undefined) |
| ≥95 (fixed resistance) | 46.7 (7/15) | 4.74 (2.38–9.44) |
| Strain heterogeneity | ||
| Single strain | 11.0 (19/173) | 1.00 |
| Possible mixed strains | 9.1 (6/66) | 0.83 (.35–1.98) |
| Mixed strains | 23.8 (5/21) | 2.17 (.90–5.20) |
| Characteristic . | Poor Outcome, % (Proportion) . | Risk Ratio (95% CI) . |
|---|---|---|
| Sex | ||
| Male | 9.7 (15/155) | 1.00 |
| Female | 14.3 (15/105) | 1.48 (.75–2.89) |
| Age, y | ||
| <21 | 3.8 (1/26) | 1.00 |
| 21–30 | 5.5 (4/73) | 1.42 (.17–12.17) |
| 31–40 | 15.5 (13/84) | 4.02 (.55–29.31) |
| 41–50 | 17.1 (7/41) | 4.44 (.58–34.03) |
| ≥51 | 14.7 (5/34) | 3.82 (.48–30.77) |
| Prior history of tuberculosis | ||
| No | 10.9 (24/220) | 1.00 |
| Yes | 15.0 (6/40) | 1.38 (.60–3.15) |
| Treatment category | ||
| New | 11.7 (26/223) | 1.00 |
| Retreatment | 10.8 (4/37) | 0.93 (.34–2.50) |
| HIV status | ||
| Negative | 4.3 (5/116) | 1.00 |
| Positive | 17.1 (24/140) | 3.98 (1.57–10.10) |
| Phenotypic DST result | ||
| INH and RIF susceptible | 9.5 (21/221) | 1.00 |
| INH monoresistance | 27.3 (3/11) | 2.87 (1.01–8.18) |
| RIF monoresistance | 25.0 (1/4) | 2.63 (.46–15.07) |
| Multidrug resistance | 80.0 (4/5) | 8.42 (4.63–15.31) |
| Resistance mutation frequency, % | ||
| <0.1 | 9.8 (19/193) | 1.00 |
| 0.1–4.9 (micro-heteroresistance) | 3.2 (1/31) | 0.33 (.05–2.36) |
| 5.0–94.9 (macro-heteroresistance) | 0.0 (0/2) | 0.00 (Undefined) |
| ≥95 (fixed resistance) | 46.7 (7/15) | 4.74 (2.38–9.44) |
| Strain heterogeneity | ||
| Single strain | 11.0 (19/173) | 1.00 |
| Possible mixed strains | 9.1 (6/66) | 0.83 (.35–1.98) |
| Mixed strains | 23.8 (5/21) | 2.17 (.90–5.20) |
Abbreviations: CI, confidence interval; DST, drug susceptibility test; HIV, human immunodeficiency virus; INH, isoniazid; RIF, rifampicin.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
